Is COVID-19 on the rise again with new variants Eris and BA.2.86?

COVID-19 is making a comeback and it could be devastating. The World Health Organisation and the Centres for Disease Control and Prevention in the United States are on alert for a new, severely altered lineage of the virus that causes COVID-19. Six cases in four countries have been detected since late July. Scientists are keeping an eye on the new lineage, named BA.2.86, because it has 36 mutations that distinguish it from the currently-dominant XBB.1.5 variant. So far there is no evidence that BA.2.86 spreads faster or causes more serious illness than previous versions. The CDC said its advice on protecting yourself from COVID remains the same. Should we be concerned? What is new about COVID? COVID infections and hospitalisations have been rising in the US, Europe and Asia, with more cases in recent months attributed to the EG.5 “ Eris” subvariant, a descendant of the Omicron lineage that originally emerged in November 2021. [caption id=“attachment_13019682” align=“alignnone” width=“640”] In the last few days, public health officials have reported one incidence of BA.2.86 in each of the United States, the United Kingdom, and Israel, as well as three cases in Denmark. Reuters[/caption] Over the past few days, public health authorities have documented one case each of BA.2.86 in the United States, the UK, and Israel, and three cases in Denmark. What do scientists say about BA.2.86? BA.2.86 stems from an “earlier branch” of the coronavirus, so it differs from the variant targeted by current vaccines, explained Dr S Wesley Long, medical director of diagnostic microbiology at Houston Methodist Hospital. He said it remains to be seen whether BA.2.86 will be able to out-compete other strains of the virus or have any advantage in escaping immune responses from prior infection or vaccination. But many countries have drastically reduced testing of patients and their efforts to analyse the genomes of the viruses causing new COVID cases. In that situation, the trajectory of BA.2.86 “doesn’t look good right now,” given the speed at which new cases are being identified, said Dr Eric Topol, a genomics expert and director of the Scripps Research Translational Institute in La Jolla, California. Its many mutations make BA.2.86 “radically different in its structure” compared to earlier variants, Topol said. The main question, he added, is whether BA.2.86 will turn out to be highly transmissible. Do the new variants make people sicker? US emergency department visits and hospitalisations for COVID remain low, but have been rising since early July, according to data on the CDC website. So far, however, doctors have been reporting that patients seen in recent weeks, as the Eris variant has been spreading, are not as sick as those they treated during earlier waves of the pandemic. [caption id=“attachment_13019662” align=“alignnone” width=“640”] Updated COVID booster shots now being developed have been designed to target the Omicron subvariant XBB.1.5. File image/Reuters[/caption] Wider spread of BA.2.86 would likely cause more illness and death in vulnerable populations, Topol said. It is too soon to know whether BA.2.86 will cause more-severe illness. “Based on the available evidence, we do not yet know what risks, if any, (BA.2.86) may pose to the public’s health beyond what has been seen with other currently circulating lineages,” a CDC spokesperson said. Will vaccines protect against new variants? Due to the waning of the pandemic, it may have been a year or more since many people were either previously infected or vaccinated against COVID. “The vaccine is still going to provide you great defence against illness and death,” Long said. Updated COVID booster shots now being developed have been designed to target the Omicron subvariant XBB.1.5. Moderna said preliminary trial data suggest its latest version of the vaccine shows promise against Eris and a related variant called Fornax, which has begun to circulate in the US. Pfizer Inc has said its updated COVID-19 shot showed neutralising activity against the Eris subvariant in a study conducted on mice. With inputs from Reuters